<DOC>
	<DOCNO>NCT01845688</DOCNO>
	<brief_summary>The purpose study evaluate clinical safety efficacy QingReMoShen Granule treat idiopathic membranous nephropathy .</brief_summary>
	<brief_title>Clinical Study QingReMoShen Granule Treat Idiopathic Membranous Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis , Membranous</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Women men clinic biopsyproven idiopathic membranous nephropathy ; 6.0g≥24 hour urinary protein≥1.0g ; serum albumin concentration≥26g/L ; Chronic Kidney Disease ( CKD ) ≤3 stage ( eGFR＞30ml/min/1.73m2 MDRD ) ; Willing participate trial sign informed consent . Secondary membranous nephropathy ; Patients one follow circumstance malignant tumor malignancy , HIV infection , history mental illness , serious systemic infection , serious gastrointestinal disease , circulate hepatitis B surface antigen positive persistent abnormal serum transaminase , abnormal glucose metabolism diabetes mellitus ; Pregnant lactate woman ; Undergoing clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Idiopathic Membranous Nephropathy</keyword>
	<keyword>Traditional Chinese Medicine</keyword>
	<keyword>Randomized Control Trial</keyword>
</DOC>